SIGN UP
LOG IN
C
CTKB
Cytek Biosciences, Inc.
2.45
-0.03-1.21%After Hours: 2.500 +0.050 +2.04%17:57 05/22 EDT
OPEN/PREV CLOSE2.495/2.480
TODAY RANGE2.390-2.525
VOL1.37M
MARKET CAP310.32M
52 WEEK RANGE2.390-7.63
AVG VOL (3M)880.35K
% TURNOVER1.08%
TURNOVER--
P/E (TTM)-28.3565
% RANGE5.04%
EPS(TTM)-0.0864
P/E(FORWARD)-11.6667
P/B0.8235
BVPS2.975
DIVIDEND--
P/S1.579
BETA--
DIV YIELD0.00%
FREE FLOAT MKT CAP282.07M
SHARES OUTSTANDING126.66M
NEXT EARNINGS08/04-08/08
FREE FLOAT115.13M
LOT SIZE1
EX-DIV DATE--
News
Press Releases
Financial Reports
Profile
TipRanks·6d ago
Cytek Biosciences (CTKB) Gets a Buy from Piper Sandler
Dow Jones·05/12 17:14
Cytek Biosciences Is Maintained at Sell by Goldman Sachs
Dow Jones·05/12 17:14
Cytek Biosciences Price Target Cut to $3.00/Share From $3.50 by Goldman Sachs
Benzinga·05/12 17:03
Goldman Sachs Maintains Sell on Cytek Biosciences, Lowers Price Target to $3
TipRanks·05/10 00:48
Cytek Biosciences: Earnings Call Reveals Mixed Fortunes
TipRanks·05/09 15:18
Piper Sandler Sticks to Its Buy Rating for Cytek Biosciences (CTKB)
TipRanks·05/09 10:01
Cytek Biosciences downgraded to Hold from Buy at TD Cowen
Reuters·05/09 07:07
U.S. RESEARCH ROUNDUP-Certara, Curtiss-Wright, McKesson
TipRanks·05/09 04:45
Cytek Biosciences Reports Q1 2025 Financial Results
Seeking Alpha·05/08 20:57
Cytek Biosciences GAAP EPS of -$0.09 misses by $0.04, revenue of $41.5M misses by $1.16M
TipRanks·05/08 20:50
Cytek Biosciences cuts FY25 revenue view to $196M-$210M from $204M-$212M
Same Industry
Name/Symbol
Change%
Price
Risk Disclosure: The content of this page is not an investment advice and does not constitute any offer or solicitation to offer or recommendation of any investment product. It is for general purposes only and does not take into account your individual needs, investment objectives and specific financial circumstances. All investments involve risk and the past performance of securities, or financial products does not guarantee future results or returns. Keep in mind that while diversification may help spread risk it does not assure a profit, or protect against loss, in a down market. There is always the potential of losing money when you invest in securities, or other financial products. Investors should consider their investment objectives and risks carefully before investing. For more details, please refer to risk disclosure.
① During the campaign period, US stocks, US stocks short selling, US stock options, Hong Kong stocks, and A-shares trading will maintain at $0 commission, and no subscription/redemption fees for mutual fund transactions. $0 fee offer has a time limit, until further notice. For more information, please visit: https://www.webull.hk/pricing
Webull Securities Limited is licensed with the Securities and Futures Commission of Hong Kong (CE No. BNG700) for carrying out Type 1 License for Dealing in Securities, Type 2 License for Dealing in Futures Contracts and Type 4 License for Advising on Securities.
① During the campaign period, US stocks, US stocks short selling, US stock options, Hong Kong stocks, and A-shares trading will maintain at $0 commission, and no subscription/redemption fees for mutual fund transactions. $0 fee offer has a time limit, until further notice. For more information, please visit: https://www.webull.hk/pricing
Webull Securities Limited is licensed with the Securities and Futures Commission of Hong Kong (CE No. BNG700) for carrying out Type 1 License for Dealing in Securities, Type 2 License for Dealing in Futures Contracts and Type 4 License for Advising on Securities.
Language
English
©2025 Webull Securities Limited. All rights reserved.